Personalized medicine in oncology: a personal view with myths and facts [0.03%]
肿瘤学的个体化医疗：个人见解（穿插神话与事实）
Jos H Beijnen,Jan H M Schellens
Jos H Beijnen
Personalized treatments with molecularly targeted agents are considered new and heading towards a bright future in medical oncology. The development of imatinib was a landmark and its clinical and commercial success revolutionized many new ...
Martine E D Chamuleau,Arjan A van de Loosdrecht,Peter C Huijgens
Martine E D Chamuleau
This review focuses on the development of monoclonal antibodies that have been or are being introduced in the treatment of both lymphoid and myeloid haematological malignancies in adults. After a general introduction on the principles of an...
Ben Markman,Josep Tabernero
Ben Markman
Monoclonal antibodies (mAbs) have become an integral part of therapeutic strategies used to treat solid tumours. Directed against membrane-bound receptors or extracellular ligands with high specificity, they target elements upstream in the ...
Molecular targeted therapy in prevalent tumors: learning from the past and future perspectives [0.03%]
常见肿瘤的分子靶向治疗：回顾过去和未来展望
Otto Metzger-Filho,Camilo Moulin,Ahmad Awada
Otto Metzger-Filho
Important advances have been achieved with molecular targeted agents in clinical oncology. Breast, colon, and lung cancer, are now commonly treated with a combination of chemotherapy and targeted agents. In this article the authors discuss ...
Laura G M Daenen,Jeanine M L Roodhart,Yuval Shaked et al.
Laura G M Daenen et al.
Vascular disrupting agents (VDAs) represent a novel class of drugs targeting the tumor's blood supply. Conceptually and operationally different from currently used antiangiogenic agents, VDAs have a high specificity for the established but ...
Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents [0.03%]
G2检查点通过Wee-1激酶抑制作用被废除，导致p53缺陷型肿瘤细胞对DNA损伤剂敏感化
Suzanne Leijen,Jos H Beijnen,Jan H M Schellens
Suzanne Leijen
Inducing DNA damage is a well known strategy for attacking cancer, already being used for many years by the application of a variety of anti cancer drugs. Tumor cells and other rapidly dividing cells are more sensitive to DNA damage caused ...
David S Boss,Jos H Beijnen,Jan H M Schellens
David S Boss
The enzyme poly(ADP)-ribose polymerase-1 (PARP-1) plays an important role in the repair of DNA damage via a mechanism called base excision repair (BER). Initially, inhibition of PARP-1 showed to be a promising anti-tumor strategy in preclin...
Role of histone deacetylases and their inhibitors in cancer biology and treatment [0.03%]
组蛋白去乙酰化酶及其抑制剂在癌症生物学和治疗中的作用
Jan H Beumer,Hussein Tawbi
Jan H Beumer
Histone deacetylase (HDAC) inhibitors constitute a new group of epigenetic agents that has gained much attention in cancer drug development. Research in the field of epigenetics is furthering our understanding of malignant behavior and prov...
Ken-ichi Fujita,Alex Sparreboom
Ken-ichi Fujita
Irinotecan (CPT-11) is a widely used anticancer drug, especially for the treatment of colorectal cancer. Irinotecan is considered an inactive prodrug that requires activation to the active metabolite SN-38. Patients treated with irinotecan ...
DNA vaccination in oncology: current status, opportunities and perspectives [0.03%]
肿瘤学中的DNA疫苗：现状、机遇与前景
Joost H van den Berg,Koen Oosterhuis,Jos H Beijnen et al.
Joost H van den Berg et al.
After almost 20 years of research, DNA vaccination is still a relatively young technique in the vaccine-toolbox. DNA vaccines can easily be modified by conventional cloning techniques, are relatively easy to produce and might be particularl...